메뉴 건너뛰기




Volumn 149, Issue 1, 2015, Pages 5-15

HER2-family signalling mechanisms, clinical implications and targeting in breast cancer

Author keywords

Breast cancer; HER2; PI3 K; Trastuzumab

Indexed keywords

AFATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; LAPATINIB; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

EID: 84925462746     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-3250-x     Document Type: Review
Times cited : (71)

References (96)
  • 2
    • 35148885729 scopus 로고    scopus 로고
    • A functional genetic approach identifies the PI3 K pathway as a major determinant of trastuzumab resistance in breast cancer
    • COI: 1:CAS:528:DC%2BD2sXht1ais7zL, PID: 17936563
    • Berns K, Horlings HM, Hennessy BT et al (2007) A functional genetic approach identifies the PI3 K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12:395–402
    • (2007) Cancer Cell , vol.12 , pp. 395-402
    • Berns, K.1    Horlings, H.M.2    Hennessy, B.T.3
  • 3
    • 0042208398 scopus 로고    scopus 로고
    • The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy
    • COI: 1:CAS:528:DC%2BD3sXmvFSqt74%3D, PID: 12897328
    • Ross JS, Fletcher JA, Linette GP et al (2003) The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 8:307–325
    • (2003) Oncologist , vol.8 , pp. 307-325
    • Ross, J.S.1    Fletcher, J.A.2    Linette, G.P.3
  • 4
    • 0037434791 scopus 로고    scopus 로고
    • Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
    • COI: 1:CAS:528:DC%2BD3sXhsV2rtrw%3D, PID: 12610629
    • Cho HS, Mason K, Ramyar KX et al (2003) Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421:756–760
    • (2003) Nature , vol.421 , pp. 756-760
    • Cho, H.S.1    Mason, K.2    Ramyar, K.X.3
  • 5
    • 0029829040 scopus 로고    scopus 로고
    • The epidermal growth factor receptor couples transforming growth factor-alpha, heparin-binding epidermal growth factor-like factor, and amphiregulin to Neu, ErbB-3, and ErbB-4
    • COI: 1:CAS:528:DyaK28XltVKrtr4%3D, PID: 8702723
    • Riese DJ, Kim ED, Elenius K et al (1996) The epidermal growth factor receptor couples transforming growth factor-alpha, heparin-binding epidermal growth factor-like factor, and amphiregulin to Neu, ErbB-3, and ErbB-4. J Biol Chem 271:20047–20052
    • (1996) J Biol Chem , vol.271 , pp. 20047-20052
    • Riese, D.J.1    Kim, E.D.2    Elenius, K.3
  • 6
    • 84877028141 scopus 로고    scopus 로고
    • Comprehensive molecular portraits of human breast tumours
    • Cancer Genome Atlas N (2012) Comprehensive molecular portraits of human breast tumours. Nature 490:61–70
    • (2012) Nature , vol.490 , pp. 61-70
    • Cancer Genome Atlas, N.1
  • 7
    • 0029838204 scopus 로고    scopus 로고
    • Mutations affecting conserved cysteine residues within the extracellular domain of Neu promote receptor dimerization and activation
    • COI: 1:CAS:528:DyaK28Xlt1Citbo%3D, PID: 8799121
    • Siegel PM, Muller WJ (1996) Mutations affecting conserved cysteine residues within the extracellular domain of Neu promote receptor dimerization and activation. Proc Natl Acad Sci USA 93:8878–8883
    • (1996) Proc Natl Acad Sci USA , vol.93 , pp. 8878-8883
    • Siegel, P.M.1    Muller, W.J.2
  • 8
    • 0030944455 scopus 로고    scopus 로고
    • ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling
    • COI: 1:CAS:528:DyaK2sXislKltLo%3D, PID: 9130710
    • Graus-Porta D, Beerli RR, Daly JM, Hynes NE (1997) ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 16:1647–1655
    • (1997) EMBO J , vol.16 , pp. 1647-1655
    • Graus-Porta, D.1    Beerli, R.R.2    Daly, J.M.3    Hynes, N.E.4
  • 9
    • 0023822220 scopus 로고
    • Oncogenic activation of p185neu stimulates tyrosine phosphorylation in vivo
    • COI: 1:CAS:528:DyaL1cXls1yiurg%3D, PID: 2464744
    • Stern DF, Kamps MP, Cao H (1988) Oncogenic activation of p185neu stimulates tyrosine phosphorylation in vivo. Mol Cell Biol 8:3969–3973
    • (1988) Mol Cell Biol , vol.8 , pp. 3969-3973
    • Stern, D.F.1    Kamps, M.P.2    Cao, H.3
  • 10
    • 84870356223 scopus 로고    scopus 로고
    • Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping
    • COI: 1:CAS:528:DC%2BC38XhslKgurjI, PID: 23045247
    • Wulfkuhle JD, Berg D, Wolff C et al (2012) Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping. Clin Cancer Res 18:6426–6435
    • (2012) Clin Cancer Res , vol.18 , pp. 6426-6435
    • Wulfkuhle, J.D.1    Berg, D.2    Wolff, C.3
  • 11
    • 0042307325 scopus 로고    scopus 로고
    • The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation
    • COI: 1:CAS:528:DC%2BD3sXlvVyitbY%3D, PID: 12853564
    • Holbro T, Beerli RR, Maurer F et al (2003) The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA 100:8933–8938
    • (2003) Proc Natl Acad Sci USA , vol.100 , pp. 8933-8938
    • Holbro, T.1    Beerli, R.R.2    Maurer, F.3
  • 12
    • 84884279586 scopus 로고    scopus 로고
    • HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer
    • COI: 1:CAS:528:DC%2BC3sXhtlSitLbF, PID: 23959396
    • Lipton A, Goodman L, Leitzel K et al (2013) HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer. Breast Cancer Res Treat 141:43–53
    • (2013) Breast Cancer Res Treat , vol.141 , pp. 43-53
    • Lipton, A.1    Goodman, L.2    Leitzel, K.3
  • 13
    • 84885024224 scopus 로고    scopus 로고
    • An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin
    • COI: 1:CAS:528:DC%2BC3sXhsFGrsrnK, PID: 23928993
    • Garner AP, Bialucha CU, Sprague ER et al (2013) An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin. Cancer Res 73:6024–6035
    • (2013) Cancer Res , vol.73 , pp. 6024-6035
    • Garner, A.P.1    Bialucha, C.U.2    Sprague, E.R.3
  • 14
    • 84892724922 scopus 로고    scopus 로고
    • Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy
    • COI: 1:CAS:528:DC%2BC2cXhtFKrs7c%3D, PID: 24097864
    • Phillips GD, Fields CT, Li G et al (2014) Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy. Clin Cancer Res 20:456–468
    • (2014) Clin Cancer Res , vol.20 , pp. 456-468
    • Phillips, G.D.1    Fields, C.T.2    Li, G.3
  • 15
    • 44149098849 scopus 로고    scopus 로고
    • Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
    • PID: 18182100
    • Sassen A, Rochon J, Wild P et al (2008) Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients. Breast Cancer Res 10:R2
    • (2008) Breast Cancer Res , vol.10 , pp. 2
    • Sassen, A.1    Rochon, J.2    Wild, P.3
  • 16
    • 84906231658 scopus 로고    scopus 로고
    • Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer
    • Nafi S, Generali D, Kramer-Marek G et al (2014) Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer. Oncotarget 2014
    • (2014) Oncotarget , pp. 2014
    • Nafi, S.1    Generali, D.2    Kramer-Marek, G.3
  • 17
    • 3543024857 scopus 로고
    • Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen
    • COI: 1:CAS:528:DyaL2sXjtFWnsg%3D%3D, PID: 3466178
    • Drebin JA, Link VC, Weinberg RA, Greene MI (1986) Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen. Proc Natl Acad Sci USA 83:9129–9133
    • (1986) Proc Natl Acad Sci USA , vol.83 , pp. 9129-9133
    • Drebin, J.A.1    Link, V.C.2    Weinberg, R.A.3    Greene, M.I.4
  • 18
    • 0032127350 scopus 로고    scopus 로고
    • Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts
    • COI: 1:CAS:528:DyaK1cXksFCqt7g%3D, PID: 9661897
    • Baselga J, Norton L, Albanell J et al (1998) Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58:2825–2831
    • (1998) Cancer Res , vol.58 , pp. 2825-2831
    • Baselga, J.1    Norton, L.2    Albanell, J.3
  • 19
    • 0035874981 scopus 로고    scopus 로고
    • Trastuzumab (Herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells
    • COI: 1:CAS:528:DC%2BD3MXks1Grtbo%3D, PID: 11406546
    • Molina MA, Codony-Servat J, Albanell J et al (2001) Trastuzumab (Herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 61:4744–4749
    • (2001) Cancer Res , vol.61 , pp. 4744-4749
    • Molina, M.A.1    Codony-Servat, J.2    Albanell, J.3
  • 20
    • 0038607569 scopus 로고    scopus 로고
    • The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition
    • COI: 1:CAS:528:DC%2BD3sXkslygsLc%3D, PID: 12700233
    • Le XF, Claret FX, Lammayot A et al (2003) The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition. J Biol Chem 278:23441–23450
    • (2003) J Biol Chem , vol.278 , pp. 23441-23450
    • Le, X.F.1    Claret, F.X.2    Lammayot, A.3
  • 21
    • 0035874898 scopus 로고    scopus 로고
    • Down-regulation of the erbB-2 receptor by trastuzumab (Herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2
    • COI: 1:CAS:528:DC%2BD3MXks1Gru7g%3D, PID: 11406568
    • Cuello M, Ettenberg SA, Clark AS et al (2001) Down-regulation of the erbB-2 receptor by trastuzumab (Herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res 61:4892–4900
    • (2001) Cancer Res , vol.61 , pp. 4892-4900
    • Cuello, M.1    Ettenberg, S.A.2    Clark, A.S.3
  • 22
    • 84864310710 scopus 로고    scopus 로고
    • Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines
    • COI: 1:STN:280:DC%2BC38zntFyisg%3D%3D, PID: 22056974
    • Collins DM, O’Donovan N, McGowan PM et al (2012) Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines. Ann Oncol 23:1788–1795
    • (2012) Ann Oncol , vol.23 , pp. 1788-1795
    • Collins, D.M.1    O’Donovan, N.2    McGowan, P.M.3
  • 23
    • 4444372733 scopus 로고    scopus 로고
    • Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2
    • COI: 1:CAS:528:DC%2BD2cXntlOqtb8%3D, PID: 15355889
    • Gennari R, Menard S, Fagnoni F et al (2004) Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 10:5650–5655
    • (2004) Clin Cancer Res , vol.10 , pp. 5650-5655
    • Gennari, R.1    Menard, S.2    Fagnoni, F.3
  • 24
    • 49449112267 scopus 로고    scopus 로고
    • Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain
    • COI: 1:CAS:528:DC%2BD1cXpslWktrc%3D, PID: 18664652
    • Gril B, Palmieri D, Bronder JL et al (2008) Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst 100:1092–1103
    • (2008) J Natl Cancer Inst , vol.100 , pp. 1092-1103
    • Gril, B.1    Palmieri, D.2    Bronder, J.L.3
  • 25
    • 33847369020 scopus 로고    scopus 로고
    • Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling
    • COI: 1:CAS:528:DC%2BD2sXhvVWrsbc%3D, PID: 17308062
    • Nahta R, Yuan LX, Du Y, Esteva FJ (2007) Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling. Mol Cancer Ther 6:667–674
    • (2007) Mol Cancer Ther , vol.6 , pp. 667-674
    • Nahta, R.1    Yuan, L.X.2    Du, Y.3    Esteva, F.J.4
  • 26
    • 77951744619 scopus 로고    scopus 로고
    • Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor
    • COI: 1:CAS:528:DC%2BC3cXltlegtL4%3D, PID: 20406840
    • Scaltriti M, Chandarlapaty S, Prudkin L et al (2010) Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor. Clin Cancer Res 16:2688–2695
    • (2010) Clin Cancer Res , vol.16 , pp. 2688-2695
    • Scaltriti, M.1    Chandarlapaty, S.2    Prudkin, L.3
  • 27
    • 0037068741 scopus 로고    scopus 로고
    • Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways
    • COI: 1:CAS:528:DC%2BD38Xms1yrs7w%3D, PID: 12214266
    • Xia W, Mullin RJ, Keith BR et al (2002) Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 21:6255–6263
    • (2002) Oncogene , vol.21 , pp. 6255-6263
    • Xia, W.1    Mullin, R.J.2    Keith, B.R.3
  • 28
    • 81055127500 scopus 로고    scopus 로고
    • Lapatinib: functional genomics study leads to insights into mechanism of action
    • COI: 1:CAS:528:DC%2BC3MXhsVeltLnF, PID: 22072809
    • Gilmer TM (2011) Lapatinib: functional genomics study leads to insights into mechanism of action. Mol Cancer Ther 10:2025
    • (2011) Mol Cancer Ther , vol.10 , pp. 2025
    • Gilmer, T.M.1
  • 29
    • 63149110733 scopus 로고    scopus 로고
    • Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer
    • COI: 1:CAS:528:DC%2BD1MXitVOktLo%3D, PID: 19228746
    • Lin NU, Dieras V, Paul D et al (2009) Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 15:1452–1459
    • (2009) Clin Cancer Res , vol.15 , pp. 1452-1459
    • Lin, N.U.1    Dieras, V.2    Paul, D.3
  • 30
    • 30544450275 scopus 로고    scopus 로고
    • Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells
    • COI: 1:CAS:528:DC%2BD2MXhtVSjt7nN, PID: 16091755
    • Xia W, Gerard CM, Liu L et al (2005) Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene 24:6213–6221
    • (2005) Oncogene , vol.24 , pp. 6213-6221
    • Xia, W.1    Gerard, C.M.2    Liu, L.3
  • 31
    • 60149109196 scopus 로고    scopus 로고
    • Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity
    • COI: 1:CAS:528:DC%2BD1cXhsVKlt77K, PID: 19060928
    • Scaltriti M, Verma C, Guzman M et al (2009) Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene 28:803–814
    • (2009) Oncogene , vol.28 , pp. 803-814
    • Scaltriti, M.1    Verma, C.2    Guzman, M.3
  • 32
    • 84864066561 scopus 로고    scopus 로고
    • Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study
    • COI: 1:CAS:528:DC%2BC38Xht1ygsr7N, PID: 22689807
    • Blackwell KL, Burstein HJ, Storniolo AM et al (2012) Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol 30:2585–2592
    • (2012) J Clin Oncol , vol.30 , pp. 2585-2592
    • Blackwell, K.L.1    Burstein, H.J.2    Storniolo, A.M.3
  • 33
    • 84905920752 scopus 로고    scopus 로고
    • First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T → L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC)
    • Piccart-Gebhart MJHA, Baselga J et al (2014) First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T → L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC). JCO 32:5s
    • (2014) JCO , vol.32 , pp. 5
    • Piccart-Gebhart, M.J.H.A.1    Baselga, J.2
  • 34
    • 84866536687 scopus 로고    scopus 로고
    • Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919
    • Gelmon KA Boyle F, Kaufman B, et al (2012) Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919. JCO 30
    • (2012) JCO , pp. 30
    • Gelmon KA Boyle, F.1    Kaufman, B.2
  • 35
    • 19044380618 scopus 로고    scopus 로고
    • Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
    • COI: 1:CAS:528:DC%2BD38XmslSksL4%3D, PID: 12204533
    • Agus DB, Akita RW, Fox WD et al (2002) Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2:127–137
    • (2002) Cancer Cell , vol.2 , pp. 127-137
    • Agus, D.B.1    Akita, R.W.2    Fox, W.D.3
  • 36
    • 48649092620 scopus 로고    scopus 로고
    • A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy
    • COI: 1:CAS:528:DC%2BD1cXovVCnsbs%3D, PID: 18632642
    • Lee-Hoeflich ST, Crocker L, Yao E et al (2008) A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 68:5878–5887
    • (2008) Cancer Res , vol.68 , pp. 5878-5887
    • Lee-Hoeflich, S.T.1    Crocker, L.2    Yao, E.3
  • 37
    • 73649149433 scopus 로고    scopus 로고
    • Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models
    • COI: 1:CAS:528:DC%2BD1MXhsFGrtbnM, PID: 19934333
    • Scheuer W, Friess T, Burtscher H et al (2009) Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 69:9330–9336
    • (2009) Cancer Res , vol.69 , pp. 9330-9336
    • Scheuer, W.1    Friess, T.2    Burtscher, H.3
  • 38
  • 39
    • 33645500289 scopus 로고    scopus 로고
    • Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing
    • COI: 1:CAS:528:DC%2BD28XjsFSlurs%3D, PID: 16618769
    • Erickson HK, Park PU, Widdison WC et al (2006) Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res 66:4426–4433
    • (2006) Cancer Res , vol.66 , pp. 4426-4433
    • Erickson, H.K.1    Park, P.U.2    Widdison, W.C.3
  • 40
    • 79959700509 scopus 로고    scopus 로고
    • Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer
    • COI: 1:CAS:528:DC%2BC3MXnslehsbo%3D, PID: 20730488
    • Junttila TT, Li G, Parsons K et al (2011) Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat 128:347–356
    • (2011) Breast Cancer Res Treat , vol.128 , pp. 347-356
    • Junttila, T.T.1    Li, G.2    Parsons, K.3
  • 41
    • 84868520609 scopus 로고    scopus 로고
    • Trastuzumab emtansine for HER2-positive advanced breast cancer
    • COI: 1:CAS:528:DC%2BC38Xhs1ekt73M, PID: 23020162
    • Verma S, Miles D, Gianni L et al (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367:1783–1791
    • (2012) N Engl J Med , vol.367 , pp. 1783-1791
    • Verma, S.1    Miles, D.2    Gianni, L.3
  • 42
    • 84892959147 scopus 로고    scopus 로고
    • The immune system and response to HER2-targeted treatment in breast cancer
    • COI: 1:CAS:528:DC%2BC2cXhtlKntb0%3D, PID: 24480556
    • Bianchini G, Gianni L (2014) The immune system and response to HER2-targeted treatment in breast cancer. Lancet Oncol 15:e58–e68
    • (2014) Lancet Oncol , vol.15 , pp. 58-68
    • Bianchini, G.1    Gianni, L.2
  • 43
    • 37549036732 scopus 로고    scopus 로고
    • Fcgamma receptors as regulators of immune responses
    • COI: 1:CAS:528:DC%2BD2sXhsVKrsLnK, PID: 18064051
    • Nimmerjahn F, Ravetch JV (2008) Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 8:34–47
    • (2008) Nat Rev Immunol , vol.8 , pp. 34-47
    • Nimmerjahn, F.1    Ravetch, J.V.2
  • 44
    • 84866936718 scopus 로고    scopus 로고
    • Tumor PIK3CA mutations, lymphocyte infiltration, and recurrence-free survival in early breast cancer (BC):results from the FinHER trial
    • Loi SMS, Lambrechts D (2012) Tumor PIK3CA mutations, lymphocyte infiltration, and recurrence-free survival in early breast cancer (BC):results from the FinHER trial. Proc Am Soc Clin Oncol 30:282–290
    • (2012) Proc Am Soc Clin Oncol , vol.30 , pp. 282-290
    • Loi, S.M.S.1    Lambrechts, D.2
  • 46
    • 84875722651 scopus 로고    scopus 로고
    • Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98
    • COI: 1:CAS:528:DC%2BC3sXltVagtLc%3D, PID: 23341518
    • Loi S, Sirtaine N, Piette F et al (2013) Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 31:860–867
    • (2013) J Clin Oncol , vol.31 , pp. 860-867
    • Loi, S.1    Sirtaine, N.2    Piette, F.3
  • 47
    • 79952390627 scopus 로고    scopus 로고
    • Immune parameters affecting the efficacy of chemotherapeutic regimens
    • COI: 1:CAS:528:DC%2BC3MXis1Cgtb4%3D, PID: 21364688
    • Zitvogel L, Kepp O, Kroemer G (2011) Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 8:151–160
    • (2011) Nat Rev Clin Oncol , vol.8 , pp. 151-160
    • Zitvogel, L.1    Kepp, O.2    Kroemer, G.3
  • 48
    • 77953141926 scopus 로고    scopus 로고
    • Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer
    • COI: 1:CAS:528:DC%2BC3cXmslWgt70%3D, PID: 20484044
    • Junttila TT, Parsons K, Olsson C et al (2010) Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer. Cancer Res 70:4481–4489
    • (2010) Cancer Res , vol.70 , pp. 4481-4489
    • Junttila, T.T.1    Parsons, K.2    Olsson, C.3
  • 49
    • 84864535959 scopus 로고    scopus 로고
    • A single proteolytic cleavage within the lower hinge of trastuzumab reduces immune effector function and in vivo efficacy
    • COI: 1:CAS:528:DC%2BC3sXjsFSjtLk%3D, PID: 22873525
    • Fan X, Brezski RJ, Fa M et al (2012) A single proteolytic cleavage within the lower hinge of trastuzumab reduces immune effector function and in vivo efficacy. Breast Cancer Res 14:R116
    • (2012) Breast Cancer Res , vol.14 , pp. 116
    • Fan, X.1    Brezski, R.J.2    Fa, M.3
  • 50
    • 84886699076 scopus 로고    scopus 로고
    • Engineered protease-resistant antibodies with selectable cell-killing functions
    • COI: 1:CAS:528:DC%2BC3sXhs1yit7fN, PID: 23986451
    • Kinder M, Greenplate AR, Grugan KD et al (2013) Engineered protease-resistant antibodies with selectable cell-killing functions. J Biol Chem 288:30843–30854
    • (2013) J Biol Chem , vol.288 , pp. 30843-30854
    • Kinder, M.1    Greenplate, A.R.2    Grugan, K.D.3
  • 51
    • 79955570584 scopus 로고    scopus 로고
    • Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy
    • COI: 1:CAS:528:DC%2BC3MXlslyqt7w%3D, PID: 21482773
    • Stagg J, Loi S, Divisekera U et al (2011) Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci USA 108:7142–7147
    • (2011) Proc Natl Acad Sci USA , vol.108 , pp. 7142-7147
    • Stagg, J.1    Loi, S.2    Divisekera, U.3
  • 52
    • 77955534002 scopus 로고    scopus 로고
    • The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity
    • COI: 1:CAS:528:DC%2BC3cXhtVejs7vF, PID: 20708157
    • Park S, Jiang Z, Mortenson ED et al (2010) The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 18:160–170
    • (2010) Cancer Cell , vol.18 , pp. 160-170
    • Park, S.1    Jiang, Z.2    Mortenson, E.D.3
  • 53
    • 79952124960 scopus 로고    scopus 로고
    • CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies
    • COI: 1:CAS:528:DC%2BC3MXjsVWnsLc%3D, PID: 21193697
    • Kohrt HE, Houot R, Goldstein MJ et al (2011) CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood 117:2423–2432
    • (2011) Blood , vol.117 , pp. 2423-2432
    • Kohrt, H.E.1    Houot, R.2    Goldstein, M.J.3
  • 54
    • 84863230537 scopus 로고    scopus 로고
    • Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer
    • COI: 1:CAS:528:DC%2BC38XjsV2mtrw%3D, PID: 22326955
    • Kohrt HE, Houot R, Weiskopf K et al (2012) Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest 122:1066–1075
    • (2012) J Clin Invest , vol.122 , pp. 1066-1075
    • Kohrt, H.E.1    Houot, R.2    Weiskopf, K.3
  • 55
    • 79955570584 scopus 로고    scopus 로고
    • Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy
    • COI: 1:CAS:528:DC%2BC3MXlslyqt7w%3D, PID: 21482773
    • Stagg J, Loi S, Divisekera U et al (2011) Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci USA 108:7142–7147
    • (2011) Proc Natl Acad Sci USA , vol.108 , pp. 7142-7147
    • Stagg, J.1    Loi, S.2    Divisekera, U.3
  • 56
    • 77955534002 scopus 로고    scopus 로고
    • The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity
    • COI: 1:CAS:528:DC%2BC3cXhtVejs7vF, PID: 20708157
    • Park S, Jiang Z, Mortenson ED et al (2010) The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 18:160–170
    • (2010) Cancer Cell , vol.18 , pp. 160-170
    • Park, S.1    Jiang, Z.2    Mortenson, E.D.3
  • 57
    • 84908131966 scopus 로고    scopus 로고
    • Metastatic consequences of immune escape from NK cell cytotoxicity by human breast cancer stem cells
    • COI: 1:CAS:528:DC%2BC2cXhslCqu7fM, PID: 25164008
    • Wang B, Wang Q, Wang Z et al (2014) Metastatic consequences of immune escape from NK cell cytotoxicity by human breast cancer stem cells. Cancer Res 74:5746–5757
    • (2014) Cancer Res , vol.74 , pp. 5746-5757
    • Wang, B.1    Wang, Q.2    Wang, Z.3
  • 59
    • 0028144438 scopus 로고
    • Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer
    • COI: 1:STN:280:DyaK2c%2FosVKrtQ%3D%3D, PID: 7505195
    • Disis ML, Calenoff E, McLaughlin G et al (1994) Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 54:16–20
    • (1994) Cancer Res , vol.54 , pp. 16-20
    • Disis, M.L.1    Calenoff, E.2    McLaughlin, G.3
  • 60
    • 0028857587 scopus 로고
    • Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide
    • Peoples GE, Goedegebuure PS, Smith PS et al (1995) Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci USA 92:432436
    • (1995) Proc Natl Acad Sci USA , vol.92 , pp. 432436
    • Peoples, G.E.1    Goedegebuure, P.S.2    Smith, P.S.3
  • 61
    • 70350454497 scopus 로고    scopus 로고
    • Persistent immunity and survival after immunization with a HER2/neu (HER2) vaccine
    • Salazar L, Goodell V, O’Meara M et al (2009) Persistent immunity and survival after immunization with a HER2/neu (HER2) vaccine. J Clin Oncol 27:15s (suppl; abstr. 3010)
    • (2009) J Clin Oncol , vol.15 , pp. 27
    • Salazar, L.1    Goodell, V.2    O’Meara, M.3
  • 62
    • 84860700518 scopus 로고    scopus 로고
    • Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02
    • COI: 1:CAS:528:DC%2BC38XmsVWnur0%3D, PID: 21989902
    • Mittendorf EA, Clifton GT, Holmes JP et al (2012) Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer 118:2594–2602
    • (2012) Cancer , vol.118 , pp. 2594-2602
    • Mittendorf, E.A.1    Clifton, G.T.2    Holmes, J.P.3
  • 63
    • 54049092448 scopus 로고    scopus 로고
    • Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02
    • COI: 1:CAS:528:DC%2BD1cXht1Ggu7bK, PID: 18726994
    • Holmes JP, Gates JD, Benavides LC et al (2008) Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer 113:1666–1675
    • (2008) Cancer , vol.113 , pp. 1666-1675
    • Holmes, J.P.1    Gates, J.D.2    Benavides, L.C.3
  • 64
    • 3042745485 scopus 로고    scopus 로고
    • Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein–based vaccine
    • COI: 1:CAS:528:DC%2BD2cXptlCksrk%3D, PID: 15143085
    • Disis ML, Schiffman K, Guthrie K et al (2004) Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein–based vaccine. J Clin Oncol 22:1916–1925
    • (2004) J Clin Oncol , vol.22 , pp. 1916-1925
    • Disis, M.L.1    Schiffman, K.2    Guthrie, K.3
  • 65
    • 84977776057 scopus 로고    scopus 로고
    • Phase I dose-escalation trial of a recombinant HER2 vaccine in patients with Stage II/III HER2+ breast cancer
    • Limentani S, Dorval T, White S et al (2005) Phase I dose-escalation trial of a recombinant HER2 vaccine in patients with Stage II/III HER2+ breast cancer. J Clin Oncol 23:16s (suppl; abstr. 2520)
    • (2005) J Clin Oncol , vol.16 , pp. 23
    • Limentani, S.1    Dorval, T.2    White, S.3
  • 66
    • 73349084990 scopus 로고    scopus 로고
    • Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation
    • COI: 1:CAS:528:DC%2BC3cXhtVWis7Y%3D, PID: 19805669
    • Emens LA, Asquith JM, Leatherman JM et al (2009) Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. J Clin Oncol 27:5911–5918
    • (2009) J Clin Oncol , vol.27 , pp. 5911-5918
    • Emens, L.A.1    Asquith, J.M.2    Leatherman, J.M.3
  • 67
    • 84858780815 scopus 로고    scopus 로고
    • Cancer immunotherapy via dendritic cells
    • COI: 1:CAS:528:DC%2BC38XksVehtrY%3D, PID: 22437871
    • Palucka K, Banchereau J (2012) Cancer immunotherapy via dendritic cells. Nat Rev Cancer 12:265–277
    • (2012) Nat Rev Cancer , vol.12 , pp. 265-277
    • Palucka, K.1    Banchereau, J.2
  • 68
    • 84883759491 scopus 로고    scopus 로고
    • Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives
    • COI: 1:STN:280:DC%2BC3srltVKhsA%3D%3D, PID: 23585514
    • Milani A, Sangiolo D, Montemurro F et al (2013) Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives. Ann Oncol 24:1740–1748
    • (2013) Ann Oncol , vol.24 , pp. 1740-1748
    • Milani, A.1    Sangiolo, D.2    Montemurro, F.3
  • 69
    • 12544250996 scopus 로고    scopus 로고
    • Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line
    • COI: 1:CAS:528:DC%2BD2MXns1KqsA%3D%3D, PID: 15695389
    • Nagy P, Friedlander E, Tanner M et al (2005) Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res 65:473–482
    • (2005) Cancer Res , vol.65 , pp. 473-482
    • Nagy, P.1    Friedlander, E.2    Tanner, M.3
  • 70
    • 77957352037 scopus 로고    scopus 로고
    • PTEN, PIK3CA, p-AKT, and p-p70S6 K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer
    • COI: 1:CAS:528:DC%2BC3cXhsVSqu7jO, PID: 20813970
    • Esteva FJ, Guo H, Zhang S et al (2010) PTEN, PIK3CA, p-AKT, and p-p70S6 K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol 177:1647–1656
    • (2010) Am J Pathol , vol.177 , pp. 1647-1656
    • Esteva, F.J.1    Guo, H.2    Zhang, S.3
  • 71
    • 84878762419 scopus 로고    scopus 로고
    • Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours
    • COI: 1:CAS:528:DC%2BC38XhslyltbnE, PID: 23117852
    • Browne BC, Eustace AJ, Kennedy S et al (2012) Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours. Breast Cancer Res Treat 136:717–727
    • (2012) Breast Cancer Res Treat , vol.136 , pp. 717-727
    • Browne, B.C.1    Eustace, A.J.2    Kennedy, S.3
  • 72
    • 79953745096 scopus 로고    scopus 로고
    • Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways
    • PID: 21399647
    • Zhang S, Huang WC, Li P et al (2011) Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med 17:461–469
    • (2011) Nat Med , vol.17 , pp. 461-469
    • Zhang, S.1    Huang, W.C.2    Li, P.3
  • 73
    • 31544465529 scopus 로고    scopus 로고
    • p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer
    • COI: 1:CAS:528:DC%2BD28XmtlKjug%3D%3D, PID: 16428482
    • Saez R, Molina MA, Ramsey EE et al (2006) p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer. Clin Cancer Res 12:424–431
    • (2006) Clin Cancer Res , vol.12 , pp. 424-431
    • Saez, R.1    Molina, M.A.2    Ramsey, E.E.3
  • 74
    • 84864018421 scopus 로고    scopus 로고
    • Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study
    • COI: 1:CAS:528:DC%2BC38XpvVSgtrs%3D, PID: 22493419
    • Guarneri V, Frassoldati A, Bottini A et al (2012) Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. J Clin Oncol 30:1989–1995
    • (2012) J Clin Oncol , vol.30 , pp. 1989-1995
    • Guarneri, V.1    Frassoldati, A.2    Bottini, A.3
  • 75
    • 84856265603 scopus 로고    scopus 로고
    • Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance
    • COI: 1:CAS:528:DC%2BC38Xjt1Gisbk%3D
    • Gayle SSAS, O’Regan RM, Nahta R (2012) Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance. Anti-Cancer Agents Med Chem 12:151–162
    • (2012) Anti-Cancer Agents Med Chem , vol.12 , pp. 151-162
    • Gayle, S.S.A.S.1    O’Regan, R.M.2    Nahta, R.3
  • 76
    • 51049118140 scopus 로고    scopus 로고
    • An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer
    • COI: 1:CAS:528:DC%2BD1cXpt1SqtLs%3D, PID: 18676830
    • Stemke-Hale K, Gonzalez-Angulo AM, Lluch A et al (2008) An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 68:6084–6091
    • (2008) Cancer Res , vol.68 , pp. 6084-6091
    • Stemke-Hale, K.1    Gonzalez-Angulo, A.M.2    Lluch, A.3
  • 77
    • 84977776696 scopus 로고    scopus 로고
    • Abstract P2-11-02: Understanding the biology and prognosis of PIK3CA gene mutations in primary breast cancer using gene expression profiling: A pooled analysis
    • Zardavas D FD, Borwn DM, et al (2013) Abstract P2-11-02: Understanding the biology and prognosis of PIK3CA gene mutations in primary breast cancer using gene expression profiling: A pooled analysis. Cancer Res 73
    • (2013) Cancer Res , pp. 73
    • Zardavas, D.F.D.1    Borwn, D.M.2
  • 78
    • 84880230412 scopus 로고    scopus 로고
    • Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer
    • COI: 1:CAS:528:DC%2BC3sXhtFSisbvO, PID: 23739063
    • Loi S, Michiels S, Lambrechts D et al (2013) Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer. J Natl Cancer Inst 105:960–967
    • (2013) J Natl Cancer Inst , vol.105 , pp. 960-967
    • Loi, S.1    Michiels, S.2    Lambrechts, D.3
  • 79
    • 32044466838 scopus 로고    scopus 로고
    • Exploiting the PI3 K/AKT pathway for cancer drug discovery
    • COI: 1:CAS:528:DC%2BD2MXht1yktbjI, PID: 16341064
    • Hennessy BT, Smith DL, Ram PT et al (2005) Exploiting the PI3 K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4:988–1004
    • (2005) Nat Rev Drug Discov , vol.4 , pp. 988-1004
    • Hennessy, B.T.1    Smith, D.L.2    Ram, P.T.3
  • 80
    • 84977822567 scopus 로고    scopus 로고
    • Abstract S4-06: PIK3CA mutation predicts resistance to anti-HER2/chemotherapy in primary HER2-positive/hormone-receptor-positive breast cancer—prospective analysis of 737 participants of the GeparSixto and GeparQuinto studies
    • S Loibl CD, A Schneeweis, et al (2013) Abstract S4-06: PIK3CA mutation predicts resistance to anti-HER2/chemotherapy in primary HER2-positive/hormone-receptor-positive breast cancer—prospective analysis of 737 participants of the GeparSixto and GeparQuinto studies. Cancer Res 73
    • (2013) Cancer Res , pp. 73
    • S Loibl, C.D.1    Schneeweis, A.2
  • 81
    • 84860532107 scopus 로고    scopus 로고
    • Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy
    • COI: 1:CAS:528:DC%2BC38XmsFeis74%3D, PID: 22407832
    • Garcia-Garcia C, Ibrahim YH, Serra V et al (2012) Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy. Clin Cancer Res 18:2603–2612
    • (2012) Clin Cancer Res , vol.18 , pp. 2603-2612
    • Garcia-Garcia, C.1    Ibrahim, Y.H.2    Serra, V.3
  • 82
    • 84899992665 scopus 로고    scopus 로고
    • Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial
    • COI: 1:CAS:528:DC%2BC2cXmtlWnsr4%3D, PID: 24742739
    • Andre F, O’Regan R, Ozguroglu M et al (2014) Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 15:580–591
    • (2014) Lancet Oncol , vol.15 , pp. 580-591
    • Andre, F.1    O’Regan, R.2    Ozguroglu, M.3
  • 83
    • 23844438209 scopus 로고    scopus 로고
    • Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition
    • COI: 1:CAS:528:DC%2BD2MXns1Wrt7c%3D, PID: 16103051
    • Sun SY, Rosenberg LM, Wang X et al (2005) Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 65:7052–7058
    • (2005) Cancer Res , vol.65 , pp. 7052-7058
    • Sun, S.Y.1    Rosenberg, L.M.2    Wang, X.3
  • 84
    • 51849111524 scopus 로고    scopus 로고
    • NVP-BEZ235, a dual PI3 K/mTOR inhibitor, prevents PI3 K signaling and inhibits the growth of cancer cells with activating PI3 K mutations
    • COI: 1:CAS:528:DC%2BD1cXhtF2msLrK, PID: 18829560
    • Serra V, Markman B, Scaltriti M et al (2008) NVP-BEZ235, a dual PI3 K/mTOR inhibitor, prevents PI3 K signaling and inhibits the growth of cancer cells with activating PI3 K mutations. Cancer Res 68:8022–8030
    • (2008) Cancer Res , vol.68 , pp. 8022-8030
    • Serra, V.1    Markman, B.2    Scaltriti, M.3
  • 85
    • 84887453307 scopus 로고    scopus 로고
    • BAY 80-6946 is a highly selective intravenous PI3 K inhibitor with potent p110alpha and p110delta activities in tumor cell lines and xenograft models
    • COI: 1:CAS:528:DC%2BC3sXhslarsrrM, PID: 24170767
    • Liu N, Rowley BR, Bull CO et al (2013) BAY 80-6946 is a highly selective intravenous PI3 K inhibitor with potent p110alpha and p110delta activities in tumor cell lines and xenograft models. Mol Cancer Ther 12:2319–2330
    • (2013) Mol Cancer Ther , vol.12 , pp. 2319-2330
    • Liu, N.1    Rowley, B.R.2    Bull, C.O.3
  • 87
    • 65349101151 scopus 로고    scopus 로고
    • Ligand-independent HER2/HER3/PI3 K complex is disrupted by trastuzumab and is effectively inhibited by the PI3 K inhibitor GDC-0941
    • COI: 1:CAS:528:DC%2BD1MXmvVGitrg%3D, PID: 19411071
    • Junttila TT, Akita RW, Parsons K et al (2009) Ligand-independent HER2/HER3/PI3 K complex is disrupted by trastuzumab and is effectively inhibited by the PI3 K inhibitor GDC-0941. Cancer Cell 15:429–440
    • (2009) Cancer Cell , vol.15 , pp. 429-440
    • Junttila, T.T.1    Akita, R.W.2    Parsons, K.3
  • 88
    • 84898730243 scopus 로고    scopus 로고
    • Phase Ib study of buparlisib plus trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on trastuzumab-based therapy
    • COI: 1:CAS:528:DC%2BC2cXls1ehsrg%3D, PID: 24470511
    • Saura C, Bendell J, Jerusalem G et al (2014) Phase Ib study of buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on trastuzumab-based therapy. Clin Cancer Res 20:1935–1945
    • (2014) Clin Cancer Res , vol.20 , pp. 1935-1945
    • Saura, C.1    Bendell, J.2    Jerusalem, G.3
  • 89
    • 2542582261 scopus 로고    scopus 로고
    • Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase
    • COI: 1:CAS:528:DC%2BD2cXksVKns7o%3D, PID: 15173008
    • Rabindran SK, Discafani CM, Rosfjord EC et al (2004) Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res 64:3958–3965
    • (2004) Cancer Res , vol.64 , pp. 3958-3965
    • Rabindran, S.K.1    Discafani, C.M.2    Rosfjord, E.C.3
  • 90
    • 84886737613 scopus 로고    scopus 로고
    • Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
    • PID: 24009064
    • Canonici A, Gijsen M, Mullooly M et al (2013) Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer. Oncotarget 4:1592–1605
    • (2013) Oncotarget , vol.4 , pp. 1592-1605
    • Canonici, A.1    Gijsen, M.2    Mullooly, M.3
  • 91
    • 84871595073 scopus 로고    scopus 로고
    • Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy
    • COI: 1:STN:280:DC%2BC38bmtFCqsA%3D%3D, PID: 22967996
    • Awada A, Dirix L, Manso Sanchez L et al (2013) Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy. Ann Oncol 24:109–116
    • (2013) Ann Oncol , vol.24 , pp. 109-116
    • Awada, A.1    Dirix, L.2    Manso Sanchez, L.3
  • 92
    • 84873918443 scopus 로고    scopus 로고
    • Activating HER2 mutations in HER2 gene amplification negative breast cancer
    • COI: 1:CAS:528:DC%2BC3sXis1Wktrg%3D, PID: 23220880
    • Bose R, Kavuri SM, Searleman AC et al (2013) Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov 3:224–237
    • (2013) Cancer Discov , vol.3 , pp. 224-237
    • Bose, R.1    Kavuri, S.M.2    Searleman, A.C.3
  • 93
    • 49149118719 scopus 로고    scopus 로고
    • BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
    • COI: 1:CAS:528:DC%2BD1cXptlKnsbk%3D, PID: 18408761
    • Li D, Ambrogio L, Shimamura T et al (2008) BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27:4702–4711
    • (2008) Oncogene , vol.27 , pp. 4702-4711
    • Li, D.1    Ambrogio, L.2    Shimamura, T.3
  • 94
    • 84863715765 scopus 로고    scopus 로고
    • A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab
    • COI: 1:CAS:528:DC%2BC38XpvFeqsLg%3D, PID: 22418700
    • Lin NU, Winer EP, Wheatley D et al (2012) A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Res Treat 133:1057–1065
    • (2012) Breast Cancer Res Treat , vol.133 , pp. 1057-1065
    • Lin, N.U.1    Winer, E.P.2    Wheatley, D.3
  • 95
    • 84868191989 scopus 로고    scopus 로고
    • A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer
    • COI: 1:CAS:528:DC%2BC38XhtFCrsrzO, PID: 22763464
    • Schuler M, Awada A, Harter P et al (2012) A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer. Breast Cancer Res Treat 134:1149–1159
    • (2012) Breast Cancer Res Treat , vol.134 , pp. 1149-1159
    • Schuler, M.1    Awada, A.2    Harter, P.3
  • 96
    • 84870635223 scopus 로고    scopus 로고
    • A neoadjuvant, randomized, open-label phase II trial of afatinib (A) versus trastuzumab (T) versus lapatinib (L) in patients (pts) with locally advanced HER2-positive breast cancer (BC)
    • Rimawi MF, Aleixo S, Rozas AA, et al (2012) A neoadjuvant, randomized, open-label phase II trial of afatinib (A) versus trastuzumab (T) versus lapatinib (L) in patients (pts) with locally advanced HER2-positive breast cancer (BC). JCO 30
    • (2012) JCO , pp. 30
    • Rimawi, M.F.1    Aleixo, S.2    Rozas, A.A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.